Impact of resection on survival of IDH1-mut WHO II astrocytoma after malignant progression.

Related Articles

Impact of resection on survival of IDH1-mut WHO II astrocytoma after malignant progression.

World Neurosurg. 2017 Apr 01;:

Authors: Grau SJ, Hampl JA, Kohl AC, Timmer M, Duval IV, Blau T, Ruge MI, Goldbrunner RH

Abstract
OBJECTIVE: To evaluate the impact of surgical resection and adjuvant treatment on the course of patients after malignant progression of previously treated IDH1 mutated WHO II astrocytoma.
METHODS: This retrospective study explored 56 patients undergoing tumor resection for malignant progression after previously treated IDH1 mutated WHO grade II astrocytoma. We analyzed survival after malignant progression, overall survival, and identified prognostic factors using Kaplan-Meier estimates and Log rank test.
RESULTS: By the time of malignant transformation median age was 44 years, and median KPS score was 90. Complete resection of contrast enhancing tissue was achieved in 18 (32.1%) patients. Median survival after re-resection was 33 months [95%CI 20-46] months; median overall survival was 123 months [95%CI 77-170]. Gross total tumor resection, postoperative KPS score >80, adjuvant radio-chemotherapy and prior radiotherapy significantly correlated with post malignant progression survival.
CONCLUSION: Patients in good clinical condition with malignant progression of previously treated low grade gliomas should receive aggressive treatment including re-resection.

PMID: 28377251 [PubMed - as supplied by publisher]

http://ift.tt/2nNIL5C